UK Clinical Vaccine Network Conference 2022

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

It is with great excitement that we can announce this year’s Clinical Vaccine Network Conference will be held in person at the Royal College of Physicians, London.

Hosted on the 30th June, this event will cover a wide spectrum of issues in vaccine development, presentations on the latest research, and the future of vaccines.

Whilst this conference will be made available to join virtually we thoroughly recommend attending in person to not miss out on this excellent networking opportunity. There will be an array of UK healthcare professionals, and other relevant decision makers who have a specific interest in vaccine intervention in the patient pathway.

Please share the flyer for the event available here with your colleagues.

If you have any queries, or would like to enquire about sponsorship of this event, please contact: debbie@pagemedical.co.uk.

@CVN_UK

Seqirus has sponsored this conference but has had no input into the arrangements or the content except the session on “Improving Influenza Vaccine Uptake” which has specifically been sponsored and arranged by Seqirus.

To view the recordings from the online UK Clinical Vaccine Network Conference held in 2020 please click here Clinical Vaccines Network Virtual Conference 2020

Professor Teresa Lambe

Teresa Lambe is a Professor of Vaccinology & Immunology and the Calleva Head of Vaccine Immunology at the University of Oxford. She is leading a research group which improves human health by controlling disease through vaccination – stopping epidemics before they become pandemics. Her team work on emerging and outbreak pathogens including Ebola, CCHF and SARS CoV-2. Prof Lambe is one of the Principal Investigators overseeing the Oxford/AstraZeneca vaccine programme. In January 2020, Prof. Lambe co-designed the vaccine, led the preclinical studies, and oversaw the delivery of the immune results needed to support regulatory approval in late 2020.

Top